Compare NWPX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | ESPR |
|---|---|---|
| Founded | 1966 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 793.7M |
| IPO Year | 1995 | 2013 |
| Metric | NWPX | ESPR |
|---|---|---|
| Price | $74.67 | $3.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $60.00 | $6.67 |
| AVG Volume (30 Days) | 91.2K | ★ 4.4M |
| Earning Date | 02-25-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.50 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $519,991,000.00 | $303,802,000.00 |
| Revenue This Year | $8.18 | $27.49 |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | $20.26 | ★ N/A |
| Revenue Growth | ★ 7.64 | 2.83 |
| 52 Week Low | $36.97 | $0.69 |
| 52 Week High | $77.43 | $4.18 |
| Indicator | NWPX | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 63.92 | 49.78 |
| Support Level | $68.13 | $3.16 |
| Resistance Level | $77.43 | $3.52 |
| Average True Range (ATR) | 2.44 | 0.19 |
| MACD | 0.32 | 0.02 |
| Stochastic Oscillator | 63.53 | 53.12 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products. The Company is the manufacturer of engineered water transmission systems in North America and produces steel casing pipe, bar-wrapped concrete cylinder pipe, and pipeline system joints and fittings through its Engineered Steel Pressure Pipe segment. The Company provides solution-based products for a wide range of markets, including high-quality reinforced precast concrete products, lined precast sanitary sewer system components, water distribution and management equipment, including pump lift stations, wastewater pretreatment, and stormwater quality products through its Precast Infrastructure and Engineered Systems segment.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.